INTRODUCTION
The "Guide to Inspections of Blood Banks" is a consolidation of information previously provided in the Blood Bank Inspection Checklist and Report, and the Instruction Booklet for Blood Bank Inspection Checklist and Report, FDA-2609. This guide, which provides the most updated interpretation of certain regulations and guidelines, was prepared by the FDA, Office of Regulatory Affairs and the Center for Biologics Evaluation and Research.
The Blood Bank Inspection Checklist and Report, and the Instruction Booklet for Blood Bank and how many are directed.
Determine which products are prepared and activities conducted.
Licensed establishments are required to report changes in manufacturing to CBER. Some establishments submit SOPs in reporting these changes. Not all procedures are reviewed by CBER; therefore, if an investigator observes a procedure s/he considers unsafe for the donor or that will affect the safety, purity, or potency of the product contact the Division of Inspections and Surveillance at (301)-594-1191. Refer also to the July 21, 1992 memorandum, "Changes in Equipment for Processing Blood Donor Samples."
If the facility being inspected is licensed and pheresis products, i.e, Platelets, Pheresis and Fresh Frozen Plasma, are prepared by automated methods at other locations, the firm's license should be amended to permit these products collected at the other locations to be shipped in interstate commerce.
Leukocytes, granulocytes and monocytes collected by apheresis are not licensed blood components. If these are shipped interstate, the license number must not be on the product label and the product is not to be sold, bartered, or exchanged.
RECORDS
In mass production of components, the on-site supervisor, or other responsible person, reviewing and approving the records may sign as the responsible person for each group of products prepared. For licensed blood banks, this procedure should receive approval from CBER.
Records must be maintained to prevent the distribution of subsequent units of blood drawn from unsuitable donors. Unsuitable donors include, but are not limited to, those who test repeatedly reactive for anti-HIV or HBsAg and have not been properly reentered or have a medical history which would preclude donation. The regulations do not prohibit firms from collecting blood from deferred donors. A firm may collect blood from deferred donors if it is not precluded by its SOP; however, the firm must have a system to prevent the distribution of these blood components.
Refer to FDA recommendations in current memoranda to registered blood establishments and/or the establishment's SOP's to determine that the appropriate disposition of blood components and deferral of donors occurs for units testing repeatedly reactive.
ERRORS, ACCIDENTS AND FATALITIES
Refer to CBER's memorandum to registered blood establishments, dated March 20, 1991, 
titled "Responsibilities of Blood Establishments Related to Errors and Accidents in the
Manufacture of Blood and Blood Components".
Currently, there is no regulation that requires unlicensed, registered blood establishments or transfusion facilities to submit error and accident reports to the FDA. However, a thorough investigation and documentation of corrective action is required. A request has issued for unlicensed facilities and transfusion services to voluntarily report errors and accidents.
When a complication of blood collection or transfusion is confirmed to be fatal, the fatality must be reported to the Office of Compliance, 301-594-1194 , by the collecting blood bank or by the facility that performed the compatibility test. This requirement is for any facility in which the fatality occurred.
In the event that the investigator becomes aware of a previously unreported fatal donor or recipient reaction which occurred since the last inspection, the Director, Division of Inspections and Surveillance, 301-594-1194, should be notified as soon as possible.
LOOKBACK POLICY
See the April 23, 1992 memorandum, "Revised Recommendations for the Prevention of Human Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products" for additional guidance.
POST DONATION INFORMATION REPORTS
Refer to CBER's memorandum to industry titled "Guidance Regarding Post Donation Information Reports" dated December 10, 1993.
FACILITIES, EQUIPMENT, PERSONNEL FACILITIES
OSHA published the final rule for the "Occupational Exposure to Bloodborne Pathogens" in the December 6, 1991 Federal Register. Included in the rule are requirements for facilities to develop procedures to ensure the safety of employees with a potential for exposure to biohazardous materials and procedures for medical waste disposal. FDA requires hand-washing facilities for staff drawing and handling blood and the safe and sanitary disposal of trash. At some mobile sites where hand washing facilities may not be available, an alternate method to clean hands, i.e., bactericidal hand wipes, is acceptable. Unauthorized persons may not wander through an area where blood is being drawn, therefore, the traffic flow of the facility, especially mobile sites, must be properly monitored and controlled.
The interview area has to offer the donor a degree of privacy so that the donor will be comfortable answering the questions without fear of being overheard.
EQUIPMENT
Refer to the CBER July 21, 1992 Memorandum to licensed establishments on "Changes in Equipment for Processing Blood Donor Samples". Discussion of changes in equipment for ABO/RH and antibody screening is presented under Part B Laboratory below.
If equipment is used in the establishment that is not listed in the CFR, performance checks and preventive maintenance should be performed by the firm according to the manufacturer's instructions and/or SOP's.
During the course of an inspection, the investigator may observe or review instances where equipment or supplies are either being misused or not functioning as designed. Because of misuse, or lack of adherence to SOP's and/or manufacturing instructions, the use of key equipment or supplies creates circumstances where donor, operator, or product safety is compromised. It is important to examine the firm's overall use of equipment and supplies to be certain that equipment and supplies are used according to directions, satisfactorily inspected, maintained and operating properly. The standardization and calibration of the hematocrit centrifuge may be done with a commercially prepared control or by other methods, e.g., duplicate samples tested at multiple intervals.
Spectrophotometers used during viral testing should be checked periodically for linearity, drift and repeatability according to manufacturer's instructions.
Larger blood establishments may have purchased a central temperature monitoring system to monitor and record temperatures in blood storage units. Once the system is installed and its accuracy demonstrated and documented, a daily comparison of the internal thermometer to the recording chart/device is not required. However, periodic performance checks comparing calibrated thermometers to system printouts should be performed to assure the system is functioning accurately.
Procedures should provide for the calibration of the autoclave before initial use and after repairs. Calibration procedures should provide assurance that the autoclave functions as intended, i.e., sterilization of arm preparation supplies and/or decontamination of biohazardous material. Biologic indicators must be used periodically and a temperature control, such as heat sensitive tape, should be used with each run to verify that the materials are being sterilized. A minimum of 121.5oC (251oF) for 60 minutes by saturated steam at a pressure of 15 atmospheres is recommended for materials contaminated with blood; 20 minutes at the same temperature is required for arm preparation supplies.
PERSONNEL
Blood bank personnel should be familiar with applicable regulations related to their respective tasks. Personnel should know the location of the SOP manual and be knowledgeable about those sections which pertain to their jobs.
Staff of mobile sites must have the same degree of training and supervision as for fixed donor sites located in the blood bank or in a donor center. Volunteers are permitted to assist in various areas and must be adequately trained. Training should be documented.
QUALITY ASSURANCE
Refer to the "Draft Guideline for Quality Assurance in Blood Establishments", dated June 17,
1993.
This publication assists manufacturers of blood and blood components on developing procedures and practices useful for administering a quality assurance program. Facilities may follow the guideline or choose to use alternative procedures not provided in the document.
However, if an establishment chooses to use alternative procedures, the facility may wish to discuss such procedures with the FDA to prevent expenditures of resources on activities that may be unacceptable to the agency.
DISPOSAL OF INFECTIOUS WASTE
FDA advises that state and local laws should be followed. All blood contaminated waste should be autoclaved (121.5oC/251oF for 60 minutes) or incinerated. The firm's SOP should contain specific language for disposal of contaminated waste. Needles should be disposed of in a container designed to prevent accidental puncturing of personnel. If contaminated waste is disposed of by a contract waste disposal firm, a contracted agreement should be on file at the facility, and specify that Biohazardous material is disposed of appropriately according to EPA, state and/or local regulations. Inappropriate disposal practices should be referred to state authorities for follow-up. 
DONOR HISTORY
Temperature, Blood Pressure: The suggested "normal" blood pressure value is 90-180 mm/50-100 mm. A low temperature is usually of no significance unless the donor has symptoms of viral illness. Temperature conversion: oF = (oC x 9/5) + 32; oC = (oF -32) x 5/9. A temperature on the day of donation >= 99.6oF (37.5oC) would temporarily defer a donor. A temperature of 99oF (37.2oC) for more than a 10 days should be evaluated before donation would be allowed. Directed Donors: should meet all suitability requirements and be tested as allogeneic donors.
Occasionally, a directed donation may not meet all suitability and testing requirements, in which case, the patient's physician may make a medical decision to use the directed donation.
SCREENING AREA QUALITY CONTROL
The containers for the copper sulfate (CuSO4) solution must be covered when not in use so that the solution will not evaporate. In order to prevent dilution of the copper sulfate, which might result in selection of donors with inadequate hemoglobin levels, containers must be thoroughly dry before use. Generally, 25 ml vials of copper sulfate solution are used. Because the blood:copper sulfate ratio is one drop of blood:one ml of copper sulfate, the copper sulfate should be discarded after 25 donors have been tested.
The copper sulfate solution used, which is equivalent to 12.5 gm/dl hemoglobin, has a specific gravity of 1.053; CuSO4 equivalent to 13.5 gm/dl hemoglobin has a specific gravity of 1.055.
The specific gravity should be checked periodically with a calibrated hydrometer.
If there is no clear distinction between acceptable and unacceptable donors, the solutions should be changed, or a different method of screening donors should be considered. Copper sulfate screening is not a quantitative procedure. Specific measurement of hemoglobin or hematocrit may indicate that a donor rejected by the copper sulfate procedure is, after all, acceptable.
There are newer laboratory instruments available to determine Hemoglobin or Hematocrit in 
ARM PREPARATION
Commercial arm preparation supplies are prepared by several manufacturers, e.g., Clinipad
Corporation and Marion Scientific. These products are not marked sterile but may be used to prepare the donor's arm for phlebotomy.
Arm preparation supplies, such as gauze, cotton balls, and applicators may be prepared by the establishment. If the arm preparation supplies are sterilized by a central supply which is a part of a hospital's operation, it is not necessary to observe these preparation procedures or to review the records for these supplies.
Arm preparations should be done with care and for the full amount of time as stated in the SOP, and ideally with vigorous scrubbing.
There are several ways to do a satisfactory arm preparation. Sufficient duration and vigor of scrubbing are the key factors to removal of superficial microbes which is the goal of the arm preparation. The final step must be application of a bacteriostatic agent in a non-overlapping spiral beginning at the intended needle puncture site and extending outward.
BLOOD COLLECTION
After the venipuncture area is prepared, the vein may be palpated above or below the prepared area; however the site of needle insertion should not be touched prior to venipuncture. It is not permissible to put iodine or sterile gauze on the finger to palpate the intended venipuncture site. Needles may be used for only one venipuncture. If a venipuncture is unsuccessful, a new needle must be used and the arm preparation repeated.
The completion of the donation may be signaled by a trip scale or vacuum-assist method based on mass or volume. Otherwise, the bag must be weighed (spring scales) and the flow stopped manually. The blood should be mixed gently (either manually or mechanically) during collection. The final unit should weigh approximately 425-525 grams plus the weight of the container and anticoagulant (approximately 90 grams). Low volume collections, e.g., pediatric autologous collections, are acceptable providing the establishment has an SOP. For low volume collections to be shipped in interstate commerce, the facility must have CBER approval.
Hermetic sealing of the blood bag tubing is accomplished by one of the following: dielectric sealing, metal clamp, or tying a tight "white knot" in the donor tubing. The contents of the tubing should be stripped into the bag, mixed well, and the anticoagulated blood allowed to refill the tubing. Following stripping of the tubing, an additional hermetic seal should be placed close to the bag so as to prevent tampering, thereby ensuring maintenance of a closed system. Specific gravity of whole blood = 1.053 gm/mL for blood containing 12.5 gm/dL of hemoglobin. The following calculation is used to convert volume to weight: 1.053 gm/mL X 500 mL =526.5 gm There are firms with approval from CBER to collect FFP or other plasma byproducts using hemapheresis devices. Some firms are approved to aliquot the FFP (or other products) into smaller containers using a sterile tubing connecting device (STCD). An STCD is a device which seals two pieces of "like" (same size and composition) tubing together to make a sterile Collection sets must be stored in accordance with the manufacturer's instructions.
Inappropriate storage may contribute to evaporation of the anticoagulant/preservative solution, or to mold growth on the container surface.
LABORATORY SAMPLES
Pilot (laboratory) samples containing blood for ABO, Rh, antibody screening and viral testing are collected at the time of donation. The tubes must be identified to accurately relate them to the unit. The method used for collection of the pilot sample should be one that precludes contamination of the donor unit, minimizes personnel exposure to blood, and maintains donor safety. See the AABB Technical Manual, for methods of pilot sample collection.
DATING PERIOD
Expiration dates vary from 21 days for ACD, CPD, and CP2D, 35 days for CPDA-1 in whole blood and red blood cells, to 42 days for red blood cells to which additive solutions have been added, i.e., ADSOLR (Fenwal), NutricellR (Cutter) and OptisolR (Terumo).
AUTOLOGOUS BLOOD COLLECTION
Autologous units are blood or blood products collected from a person for his/her own use at a later time. These predeposited blood products are handled and processed as similarly as possible to homologous units. CBER sent the following memoranda concerning autologous donations to all registered blood establishments: "Guidance for Autologous Blood and Blood Therapeutic phlebotomies are considered to be a procedure intended to treat the patient for certain disease states, therefore, a written doctor's request should be available for the procedure. Units of blood that are collected for therapeutic phlebotomy must be fully tested and donors meet all suitability requirements if the units are to be transfused or if the plasma will be sold for further manufacture. Several recalls have occurred due to lack of testing of recovered plasma from therapeutic units prior to shipping for further manufacture.
DONOR REACTIONS
A blood bank should be aware of the nature and frequency of donor reactions. Adequate records for each reaction should be kept and should include follow-up in order to insure adequate donor protection. The blood bank's SOP manual should list and describe donor reactions it considers to be adverse, as well as the procedures to be followed for handling and investigating these reactions. Severe donor reactions may include fainting, convulsions, severe hematomas (infiltration), or injury caused by falling. Mild donor reactions include feeling faint, nauseated, or dizzy.
PART B -LABORATORY ABO AND RH TESTING, and RBC Antibody Screening
Blood Grouping Reagents are used to determine the blood group. Anti-A will agglutinate or clump group A red cells. Anti-B will agglutinate group B red cells. Anti-D is used to determine Rho (D) factor.
Licensed antisera -some establishments may "otherwise meet the requirements" for ABO and Rh licensed antibodies by producing their own antisera. If so, production records that are in compliance with the requirements for the manufacture of these products specified in 21 CFR 660, Subpart C must be kept. Licensed blood banks must have CBER approval to use such antisera.
Test methods used for ABO, Rh and antibody screening, which are different from the manufacturer's instructions, should not be cited as deviations if they are not prohibited by the manufacturer, have been demonstrated to be satisfactory, or have been approved for use by CBER. For example, the MicrotiterTM plates and GroupamaticTM machines may be used for ABO, Rh, and antibody testing. The reagents must be tested and shown to perform adequately or satisfactorily when using these techniques.
Blood which tests Rho(D) negative must be confirmed by further testing (usually Du) unless it is labeled in accordance with 21 CFR 640.5(c). Acceptable methods for further testing to confirm D negatives include use of the antiglobulin method, and use of a special channel on the Kontron Groupamatic, Olympus PK700, or the Gamma STS-M automated blood groupers.
Licensed blood establishments should have a letter from CBER approving their use of an automated blood grouper for Du testing.
Not all anti-D reagents may be used for Du testing; the package insert must include directions for Du testing.
Procedures have been approved to use reagents with the GroupamaticTM beyond the dating period, provided a proper set of controls is used. Licensed establishments should have a letter from CBER on file indicating that a protocol has been submitted and approved for this procedure. Rare reagents, e.g., anti-Jkb, anti-Leb, etc., are sometimes used beyond the expiration date; this is acceptable only if adequate controls are used and the reactivity and specificity of the reagents are documented. The reactivity and specificity of reagents are generally confirmed by testing at least one positive and one negative control sample. The negative controls are not essential for ABO reagents because the antithetical cell and serum results provide confirmation of test accuracy.
The Anti-Human Globulin (Coombs) reagent must be tested each day of use with an IgG sensitized ("Coombs" control or "check") cell.
The manufacturer's instructions specify that the storage requirement for Anti-A, Anti-B, and Anti-D reagents is between 2-8oC; however, it is accepted practice for these reagents to stay at room temperature for the duration of the working day. This will usually not diminish the potency of the products throughout the normal period of use.
AUTOMATED TESTS FOR ABO & RH TESTING
Refer to the July 21, 1992 CBER memorandum to licensed establishments on "Changes in Equipment for Processing Blood Donor Samples". This document provides specific guidance on the documentation of changes in equipment, specifically calibration, validation, parallel testing, quality control, maintenance and emergency plans. Occasionally an automated blood grouping instrument is unable to interpret an ABO or Rh result. The firm should have an SOP to follow-up with further testing to obtain a result (usually by manual methods) and to up-date the testing record (data entry and verification).
SEROLOGICAL TEST FOR SYPHILIS
All units of blood must be tested by an acceptable serological test for syphilis (STS). 
TESTING PERFORMED ON PREMISES
Refer to the following memoranda for further information: If automated testing equipment is interfaced with a computer system see section on computerization, for further guidance.
In the past, the area used for HBsAg and anti-HIV testing would, by design, be in rooms separated from other blood bank activities. This is no longer considered to be important as all blood samples should be treated as capable of transmitting an infectious disease, and Biosafety Level 2 precautions should be applied in all areas where open samples are handled.
However, if RIA procedures are used in the facility these areas still must be physically separated from other areas. Work areas, such as counter tops, should be constructed of non-porous materials and designed to permit thorough cleaning and disinfection. There should be policies to prevent excessive traffic of unauthorized personnel through viral testing areas.
PROFICIENCY TESTING
Most blood establishments will be participating in a proficiency testing program, either an inhouse developed or an established program such as the College of American Pathologists (CAP), AABB or CDC.
A proposed rule was published in the June 6, 1989, Federal Register to require that each establishment or laboratory responsible for performing FDA required tests for HBsAg and anti-HIV participate in an approved program to demonstrate proficiency in performing these tests.
The final regulation proposed by FDA has not been published, however, the final rule proposed by HCFA, which regulates laboratories receiving Medicare and Medicaid reimbursement, was published in the March 14, 1990, Federal Register. This final rule requires laboratories to have policies and procedures for an ongoing program to assure that employees are competent and maintain their competency to perform their duties.
TESTING PERFORMED BY OUTSIDE LABORATORIES
The results and interpretations of all (initial and repeat) tests performed and an explanation of any symbols or phrases used in reporting results should be provided by the testing facility to the blood bank. The blood bank should have an SOP for the interpretation of the reports obtained from outside testing laboratories and written assurance that the outside testing laboratory interprets test results according to FDA requirements. The raw test data, i.e., absorbance readings from the spectrophotometer, need not be sent to the blood bank. In 
USE OF REACTIVE UNITS of Test Results When Using Licensed Viral Marker Assays to Screen Donors".
These recommendations clarify FDA's position on the invalidation of test results when screening donor blood using licensed viral marker assays, including the use of external control reagents.
PART C -RED BLOOD CELLS OPEN SYSTEM
Blood components for transfusion are normally prepared in a closed, sterile system. Occasionally, however, the hermetic seal may be broken, thereby exposing the blood component to the outside environment. When this occurs the component should have an expiration date not to exceed 24 hours.
ADDITIVE SOLUTIONS
Manufacturers of certain blood collection systems have been approved for a room temperature eight hour hold period following the collection of whole blood prior to preparation of components. These systems are the ADSOLR solution system (anticoagulant CPD), 
RED BLOOD CELLS FROZEN AND RED BLOOD CELLS DEGLYCEROLIZED
The freezing of RBC's may be accomplished by two acceptable techniques, e.g., high concentration glycerol-slow freeze (storage at <= -65oC) and low concentration glycerol-rapid freeze (storage, usually in liquid N2, at <= -120oC). The lot numbers of solutions and containers for glycerolization and deglycerolization must be recorded. Red Blood Cells, Frozen may be stored for ten years. If units in storage have not been tested for all currently required tests, there should be a procedure to prevent mislabeling when units are thawed.
Quality control testing should be performed and the firm should take corrective action when test results are out of the firm's established parameters as stated in the SOP's. Quality control testing may include periodic sterility testing, monitoring the removal of the glycerol and the amount of the free hemoglobin in the final product, and the RBC recovery. Certain blood centers have approval for an SOP that does not require sterility checks on Red Blood Cells, Deglycerolized, on a periodic basis if the facilities where the product is prepared are monitored for cleanliness and good housekeeping procedures, including proper maintenance of air filters in the heating, ventilation and air conditioning (HVAC) system. An area of concern is that the firm has adequate procedures to assure that the final container is accurately identified to relate it to the donor. 
RED BLOOD CELLS -LEUKOCYTES REMOVED
There are several methods for removing leukocytes from RBC's. These methods include centrifugation with or without saline washing, microaggregate blood filtration, freezing and deglycerolizing, washing (using either a manual or automated method) and filtration with filters designed and approved specifically for leukocyte removal.
For units labeled "Leukocytes Removed" quality control (QC) should be performed for all the methods listed above. This monthly QC is not necessary if: (1) the unit is not labeled "Leukocytes Removed"; or (2) the leukocytes are removed as the unit is being transfused using a filter that is connected to the transfusion set by the manufacturer or at the patient's bedside. The blood bank should have SOP's stating values of acceptance for leukocyte removal and corrective action to be taken if values are outside established limits. Filters specific for leukocyte removal are sometimes connected to the transfusion set at the patient's bedside and it would not be practical to monitor the post-filtration blood for leukocyte counts. The quality control for these filters was performed by the manufacturer as part of the approval process.
Transfusion services that use filters that remove leukocytes during transfusion are not considered to be manufacturing a blood product.
IRRADIATED BLOOD
Experimental data have established that in certain immunodepressed patients transfusion of foreign immunocompetent cells (T lymphocytes) may lead to graft versus host disease (GVHD). GVHD occurs when donor T lymphocytes engraft, multiply and react against the tissues of the recipient. The radiosensitivity of these T lymphocytes is higher than that of other blood cells, so irradiation of cellular blood products before rransfusion appears to be effective in preventing the transfusion induced form of this serious complication. The AABB has recently recommended that blood components prepared from directed blood donations from first degree family members (i.e., parents, children, siblings) be irradiated to decrease the risk of GVHD. The CBER issued guidance via a July 7, 1993, memorandum titled "Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products". This document addresses manufacturing and quality assurance procedures, labeling, other aspects of production and the use of irradiated blood and blood products. It also provides background on the effects of gamma radiation on product quality & stability, guidance on license amendments, record keeping and fatality reporting. If any questionable procedures for irradiating blood are encountered during an inspection notify the Division of Inspections and Surveillance, (301) 594-1191.
RED BLOOD CELLS -RECORDS
Blood banks that prepare washed, frozen, deglycerolized and rejuvenated RBC's must record the lot numbers of solutions and/or containers. The lot numbers must be traceable to the unit number.
RED BLOOD CELLS -IMMUNIZATION PROGRAMS
Refer to CBER's December 16, 1992 memorandum on the "Revision of October 7, 1988 PART D -PLASMA AND RECOVERED PLASMA Each final container of plasma for transfusion prepared from a whole blood collection shall be in an integrally attached satellite bag at the time of collection; it must be transparent and hermetically sealed by a dielectric sealer, metal clamp, or tightly drawn "white knot;" and its label must be marked by number or other symbol so that it can be traced back to the donor.
PLASMA PRODUCTS FOR TRANSFUSION
The final product should be stored in a manner which will show evidence of thawing. This may be accomplished in a variety of ways, e.g., by storing it upside down after freezing, or by placing a rubber band around the middle of the container and removing it when the unit has frozen.
RECOVERED PLASMA
Recovered Plasma is an unlicensed source material intended for use in the manufacture of both licensed and unlicensed products. A license is not required to manufacture, distribute, or pool recovered plasma.
The short supply provision allows licensed manufacturers to use unlicensed or other licensed facilities, not a part of their own establishment, to perform the initial and partial manufacturing step of collecting blood or plasma. The Recovered Plasma is shipped solely to the licensee for further manufacture into licensed injectable or noninjectable products. Short supply agreements are between the licensed fractionator and the collection facility; not with brokers. The written agreements should be up-dated periodically, and a copy of this agreement should be on file at the collecting facility. Plasma brokers may be used as authorized agents and should be identified in the short supply agreement; refer the name of the broker taking possession of the Recovered Plasma or other blood components to the home district for follow-up, i.e., registration and inspection. Short supply agreements are also required between the registered collection facility and the licensed manufacturer for other blood components (i.e., RBC's and platelets) intended for further manufacture into licensed products.
Recovered Plasma does not have an expiration date, therefore, records are to be kept indefinitely.
PART E -PLATELETS
Due to an increase in the number of post-transfusion sepsis reports, the seven day dating period for platelets reverted to five days, effective July 2, 1986. Platelets may be pooled by the blood bank personnel, upon the request of a physician; however, this is done following designation of the platelets to a specific recipient, and the resultant pool is not considered a licensed product. The label of the pooled components should indicate the individual donor numbers comprising the pool or a pool number that relates it to 
QUALITY CONTROL
Quality control testing must be performed each month platelets are prepared, using one unit obtained from each of four different donors. Platelet counts (5.5 x 1010 in 75% of the units tested), Ph determination (>= 6.0) and measurement of plasma volume should be made at the end of the storage/dating period.
If quality control testing is not under the supervision and control of the establishment, determine where the testing is performed and how test results are reviewed and handled by the establishment.
PART F -CRYOPRECIPITATED AHF (ANTIHEMOPHILIC FACTOR)
There is no volume restriction for preparing Cryoprecipitated AHF. One unit of plasma may be used as a source of both Platelets and Cryoprecipitated AHF. Practical experience has demonstrated that using careful production techniques, an acceptable final product averaging no less than 80 IU can be manufactured from a single unit. The final container should be transparent and hermetically sealed by a dielectric sealer, metal clamp, or a tight "white knot."
QUALITY CONTROL
Quality control testing need be performed only in the months in which the product is prepared.
Four units must be tested, but they may be pooled before the quality control assay is performed.
If quality control testing is not performed under the supervision of the establishment, see
Compliance Policy Guide 7134.16.
PART G -UNIFORM BLOOD LABELING
It is suggested that a label be collected for ready reference in checking the label items; however, it is important that the labels on units ready for issue are the labels in actual use and are properly completed. The Uniform Labeling Guidelines was published August 30, 1985, and the effective date was September 2, 1986 . A revised Guideline for Uniform Blood Labeling is expected to be published in the near future. Specific label information should depict reference to viral marker testing results and other tests performed, e.g. ALT.
The circulars are of great importance now that uniform or commonality labels are in use. The new labels have less information on them so that attention will be focused on the blood group (ABO and Rh). Information that has been deleted must be in the circular. The circular of information is an extension of the container labels and viewed as labeling containing statements of purported product quality. It should describe each component available for patient transfusion and give indications and contraindications for use. The blood supplier should have a plan for distributing the instruction circulars, assuring that the transfusion services have an adequate supply of the circulars, and the transfusion service should have a plan for distributing the circulars to the staff. Licensed blood banks will have submitted their circulars to CBER for approval. The firm's name and address should be on the circular.
PART H -COMPATIBILITY TESTING AND TRANSFUSION REACTIONS COMPATIBILITY TESTING
Compatibility testing should be performed in an area sufficiently removed from other areas to eliminate distraction or the introduction of errors in testing.
Hospitals may elect not to crossmatch blood for certain surgical procedures that usually do not require the transfusion of blood. This procedure is referred to as "type and screen" and requires: 1) determination of the patient's blood group; 2) tests of patient's serum for unexpected antibodies; and 3) availability of units of blood in case the patient does need blood during the operation.
See the December 14, l984, memorandum to blood establishments "Equivalent Methods for Compatibility Testing."
In addition, other methods for the compatibility testing may also be appropriate. These methods include, but, are not limited to, the use of patient specimens older than 48 hours and the use of plasma. Extended periods of time (e.g., more than three months) for holding test samples should be discussed with the Division of Inspections and Surveillance if encountered.
ANTIBODY TESTING
If an antibody screen (serum is tested with reagent red cells of known antigenic makeup to determine if there are antibodies in the serum) was performed on a unit by the supplier, the hospital or transfusion service need not repeat it, or perform a minor crossmatch.
RECIPIENT SAMPLE IDENTIFICATION
The recipient's blood sample should be identified by name and number to insure positive identification. Donor and recipient blood samples should be saved for at least seven days after transfusion in case there is a need for retesting.
EMERGENCY TRANSFUSIONS
SOP's should be available to expedite testing for transfusions in a life threatening emergency. Documentation should include signature of the requesting physician. If crossmatches are not completed sufficient documentation should be available.
COMPATIBILITY TEST RECORDS
Records should be kept of receipt of recipient's sample and the ABO and Rh test results; lot numbers of reagents used for testing; and routine and emergency crossmatches and direct antiglobulin testing (if done). The vital signs of a recipient are not required to be on file at the blood bank.
RECIPIENT ADVERSE REACTIONS
The blood bank's SOP manual should list and describe recipient reactions it considers to be adverse, as well as the procedures to be followed for handling and investigating these reactions. Recipient reactions usually not considered serious include low fever and chills of short duration, hives, or urticaria. Serious adverse recipient reactions usually include hemolysis, bacteremia, or septicemia.
If the blood bank acts as a transfusion service and receives blood from other sources, errors in the ABO and Rh grouping should be reported to the suppliers. Procedures should be established between the suppliers and users of blood and blood products for monitoring recipient adverse reactions which occur outside the supplying facility. If the supplier of mistyped blood is a licensed establishment, it is the responsibility of that establishment to Units of blood intended for autologous use should be stored in an area separate from units for allogeneic use.
STORAGE TEMPERATURE AND RECORDS
All required temperatures should be maintained. Fluctuations outside storage temperature limits must be documented as to the possible reason, and any action required to maintain the blood or components at the proper storage temperature must also be documented.
The product storage temperature after drawing is 1-6oC unless room temperature platelets are to be prepared, in which case the blood should be held at 20-24oC. If the blood must be transported from a donor center to the processing laboratory, it must be placed in temporary storage having sufficient refrigeration capacity to cool the blood continuously toward a 1-6oC range, unless platelets are to be prepared. Temperatures below 20oC (68oF) and above 24oC (75.2oF) reduce platelet function and survival. Room temperature is usually not below 20oC.
INSPECTION
Blood should be visually inspected at the time of issue for any abnormality, such as hemoglobin in the plasma from red cell lysis, purple tinged red cells due to bacterial contamination, or blood clots.
SHIPPING
Facilities should have procedures to show that shipping containers maintain products at their appropriate temperature.
REISSUE
Blood banks should have written criteria for reissuing blood that is returned to the blood bank.
Studies have shown that the unit of blood sitting at room temperature usually maintains a temperature of 10oC for 30 minutes. Blood that has been issued for transfusion may be reissued if it is returned to the blood bank within 30 minutes, and was kept at room temperature or colder while out of the blood bank's control.
PART J -PLATELETS, PHERESIS
Refer to the October, l988, memorandum from CBER to all registered blood establishments "Revised Guideline for the Collection of Platelets, Pheresis."
PART K -COMPUTERIZATION
This section will be used to evaluate USERS of computer systems, and it is not intended for use in the inspection of software developers.
Refer to the FDA "Draft Guideline for the Validation of Blood Establishment Computer Systems." This document focuses on computer system definitions, testing, manuals, maintenance, security, training, audits, FDA references and reportable activities to the FDA.
The final document will supersede the April 6, 1988, memorandum from CBER to all registered blood establishments "Recommendations for Implementation of Computerization in Blood Establishments", and the September 8, l989, memorandum "Requirements for
Computerization of Blood Establishments".
The draft guideline should be used as the main guidance document on computerized systems for registered blood establishments. However, the document is subject to change, as public comments are being collected and evaluated for incorporation into the final guideline. Specific regulations which are currently applicable are 21 CFR 606.60 (Equipment), and 21 CFR 211.68 (Automatic, mechanical, and electrical equipment) for additional information.
If a blood establishment is developing and distributing software that was originally intended for in-house use, report the number and identity of the user sites. Blood establishments developing and distributing software for use in manufacturing blood and blood components should be advised that they are a device manufacturer and be encouraged to register and list with the Center for Devices and Radiological Health.
If the software is vendor supplied, identify the developer and version. Software developers typically specify the software by a version number. When major changes have occurred in the software, a new number is assigned. If a version different from the original is in use, the facility should have procedures to test the software prior to implementation and documentation that the testing was performed.
A "shared" computer system is a system used by both the blood bank and other sections of a clinical laboratory or the entire hospital. Security procedures should have been established regarding limiting access to confidential blood bank information, e.g., donor deferral records.
In addition, access to blood bank data should be limited so that inadvertent or unauthorized changes in data do not occur.
When a decision is made regarding donor suitability and/or product quality based upon the use of and reliance on the data maintained in the computer system, the computer system is performing a critical function in the manufacture of blood and blood products. An investigator should determine how the computer system is used and relied upon in critical manufacturing steps beginning with the donation and continuing through product release.
A short description with respect to each of the areas controlled by the computer should be reported, e.g., the firm depends on the computer to check for permanent and temporary all test results received directly from the test equipment; all component processing is performed using bar coded labels; quarantine is computer controlled and if reactive test results are noted, an automatic flag is put on the unit by the computer so that the unit (components included) cannot be released for distribution.
TERMS AND ABBREVIATIONS
Allogeneic Donor -A donor who donates a unit of blood to be placed in the general blood supply. This donor must meet all suitability requirements and be fully tested.
Anti-A, Anti-B Blood Grouping Reagent -Reagents used to determine blood group: Anti-A serum, from a group B individual, will agglutinate or clump group A red cells; Anti-B serum, from a group A individual, will agglutinate or clump group B red cells. Directed Donor -A donor who donates a unit of blood for a specific patient. These donors should meet all suitability requirements and be tested as allogeneic donors. Occasionally, a directed donation may not meet all suitability and testing requirements, in which case, the patient's physician may make a medical decision to use the directed donation. Du -A variant or weak form of the D antigen; no Anti-Du reagent exists, but cells are tested for the variant by an indirect antiglobulin method, or the equivalent, such as a special channel on the Kontron Groupamatic, Olympus PK700, or Gamma STS-M automated blood groupers.
ELISA Screening Test -ELISA (also referred to as EIA) is an acronym for enzyme-linked immunosorbent assay. This assay utilizes the principle of a solid phase, e.g., beads or microtiter plate wells, coated with antigen or antibody and an indicator reagent, antibody or antigen, respectively, to which an enzyme has been conjugated or "linked."
A typical ELISA test such as that used for the detection of antibody to HIV utilizes beads or microtiter wells coated with disrupted, inactivated HIV agents and goat anti-human Ig
